CLEC2A is a novel AML-restricted immunotherapeutic target enriched in KMT2A-rearranged acute myeloid leukemia
Kirkey DC, Robinson L, Janssens D, Hines MG, Hylkema T, Manselle MK, Ries RE, Peplinski JH, Wallace LK, Otto D, Tarlock K, Henikoff S, Li W, Meshinchi S (2023) CLEC2A is a novel AML-restricted immunotherapeutic target enriched in KMT2A-rearranged acute myeloid leukemia. Blood 142(1):290. doi: 10.1182/blood-2023-188439 Objective: Targeting CLEC2A, a novel immunotherapeutic target, in the […]